Abstract
Targeting Ewing Sarcoma By Genetically and Epigenetically Modified Ex-Vivo Expanded NK Cells in Combination with NKTR-255 and Dinutuximab
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have